ClinicalTrials.gg
RecruitingNCT06361108Updated Aug 13, 2025

MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP

A Phase 1 interventional study of YJ001 for Spray Use and Placebo of YJ001 for Spray Use in Diabetic Peripheral Neuropathic Pain, sponsored by Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-13.

Sponsored by Zhejiang Hanmai Pharmaceutical Technology Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,022 studies in Diabetes Mellitus with a site in United States — 289 open to participants now, 389 under way, 12 of them phase 3. Diabetes Mellitus · United States.

Planned enrollment
1,945th of 2,501
24 · median 82
Started
2024
with 87 others
Phase 1
204 of 3,022
13 open now
Primary completion
2025-12
later than 37 of 381 live
Registered
2,782nd of 3,022
by date

Among the 3,022 studies in Diabetes Mellitus with a site in United States, this one is the 1,945th largest by planned enrollment of the 2,501 interventional ones that give a count, is one of 88 that started in 2024, is one of 204 in phase 1, reaches primary completion later than 37 of the 381 other live ones, and was the 2,782nd registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

289 of the 3,022 studies in Diabetes Mellitus with a site in United States are open now. Recruiting first, the newest first:

284 more — sign in →

All 289 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,022 studies in Diabetes Mellitus with a site in United States, or all of them as a file.
02

Study summary

This Phase I, randomized, double-blind and placebo controlled study is to evaluate the safety, tolerability, and PK, and to preliminarily assess the efficacy of topically administered YJ001 in a multiple-ascending dose (MAD) fashion in the patients with DPNP. The study will be conducted at a single study center.

In this study, 2 cohorts (N=24, 12 subjects for each cohort), each cohort will consist of 10 active and 2 placebo, with approximately equal numbers of male and female subjects.

Each subject will be administered a single dose of YJ001 as multiple sprays topically on both feet and below the ankle in the morning on Day 1 and Day 2, and will be administered as twice daily doses once in the morning and the other in the evening (with an interval of 11 to 13 h) from Day 3 through Day 11.

Read the detailed description

This Phase I, randomized, double-blind and placebo controlled study is to evaluate the safety, tolerability, and PK, and to preliminarily assess the efficacy of topically administered YJ001 in a multiple-ascending dose (MAD) fashion in the patients with DPNP between ages of 18 to 80 years. The study will be conducted at a single study center.

In this study, 2 cohorts (N=24, 12 subjects for each cohort), the doses of which are 296 mg/administration (Cohort M1) and 414 mg/administration (Cohort M2), are planned. Each cohort will enroll approximately equal numbers of male and female subjects. The administration area is set as 450 cm2 (both feet). Each subject will be administered a single dose of YJ001 as multiple sprays (16 sprays/foot for Cohort M1, and 12 sprays/foot for Cohort M2) topically on both feet and below the ankle in the morning on Day 1 and Day 2, and will be administered as twice daily doses once in the morning and the other in the evening (with an interval of 11 to 13 h) from Day 3 through Day 11.

Each cohort will consist of 12 subjects (10 active; 2 placebo), with approximately equal numbers of male and female subjects.

Each cohort will be evaluated separately for safety and PK to allow for dose escalation based on stopping criteria per protocol. The Safety Review Committee (SRC), comprised of the Principal Investigator, Medical Monitor, and Sponsor's qualified designee, will convene after completion of each cohort to evaluate available safety, PK, and other relevant data. The decision whether to escalate the dose will be made for a completed cohort based on available safety data through Day 17 (5 days post the last dose), and blinded PK data [maximum observed plasma concentration (Cmax,ss) and area under the concentration-time curve through the first 48 hours post the last dose (AUC0-48h,ss)]. The SRC will determine whether to proceed to the next planned dose level, continue with the study and add additional safety evaluations, expand the number of subjects at the current level, reduce the dose, or stop the study.

Subjects will be screened between Day -28 through Day -7, rate the scores on Numeric Rating Scale (NRS) twice daily (once in the morning and the other in the evening) from Day -7 to Day -1, and will be admitted to the clinic on Day-1. Subjects will be housed within the clinic from Day -1 through Day 17 and will be discharged on Day 17 after all scheduled study procedures have been completed. If necessary, subjects will receive a telephone follow-up 2 days post discharge for documentation of any adverse event or concomitant medication.

Safety,Pharmacokinetics and Efficacy will be evaluated.

03

Conditions studied

  • Diabetic Peripheral Neuropathic Pain

Browse trials for

Keywords

  • Diabetes
  • Diabetic Peripheral Neuropathic(DPN)
  • Diabetic Peripheral Neuropathic Pain(DPNP)
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, between the ages of 18 to 80 years at screening, both inclusive.
  • Subjects voluntarily consenting for participation in the study and having signed document. Subjects are required to understand verbal and/or written English or any other language in which a certified translation of the informed consent is available.
  • (BMI) between 19 to 42 kg/m2 (both inclusive) at screening, calculated as weight (kg)/height2 (m2). Subjects must have two feet. Each foot must have five digits. Each foot must have at least total surface area of 450 cm2 measured from below the ankle to the toes including both dorsum and plantar areas.
  • The subject is diagnosed with Type 1 or Type 2 diabetes, and has a history of DPNP for at least 3 months based on participant report or medical history.
  • The subject should have a glycemic control that has been optimized and has been stable for at least 3 months prior to randomization. The subject has used a stable regimen of antidiabetic agents (oral) and/or insulin for at least 3 months before screening.
  • (HbA1c) ≤ 10% at screening.
  • Participants who have a weekly mean score of at least 4 based upon the daily mean scores using 11-point Numeric Rating Scale (NRS) in the daily diary (rated twice daily, once in the morning and the other in the evening) from Day -7 through Day 1 (should be calculated from records 7 days immediately prior to study drug administration).
  • Males must not donate sperm until 90 days after last dose of study drug and must be willing to use a condom during heterosexual activity for up to 90 days after the application of the study drug.
  • Females must be either for at least 1 year, surgically sterile (bilateral tubal ligation [including clip, cauterization methods and coil], bilateral oophorectomy or hysterectomy, and needs to be confirmed follicle-stimulating hormone [FSH] level \>40 IU/L), or of either practicing true abstinence or practicing 2 effective means of for at least 4 weeks prior to randomization, and until 28 days after study drug administration:

    1. Intrauterine device (IUD) or IUD hormone-releasing system.
    2. Combined estrogen and progestogen containing hormonal contraception (oral, intravaginal, or transdermal) associated with inhibition of ovulation.
    3. Progesterone-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation.
    4. Intrauterine hormone-releasing system.
    5. Double-barrier method (condoms, contraceptive sponge, diaphragm, or vaginal ring with spermicide).
  • Able and willing to comply with all study requirements.

Exclusion criteria

Exclusion Criteria:

  • Current participation in another drug or device study or treated with an investigational drug within 30 days or 5 half-lives, whichever is longer, before dosing.
  • History of drug, food allergy, skin allergy, or sensitivity to drugs of the same class (e.g., 5-aminosalicylic acid, sulfasalazine, and salicylates) or known to YJ001 or any of its components.
  • History of asthma. Adults with history of benign (resolved) childhood asthma may be included.
  • Any subject who suffers severe peripheral vascular disease (e.g., intermittent claudication) at screening, and is not suitable to be involved in the study as per investigator evaluation.
  • Any subject who suffers severe cardiovascular and cerebrovascular disease (e.g., severe arrhythmia, heart failure, myocardial infarction, unstable angina pectoris, atherosclerosis, stroke, sequela of stroke, etc.), severe gastrointestinal tract disease or other serious disease (e.g., cancer) which, in the opinion of the Investigator, would prevent the subject from fully participating in the study.
  • Any subject who suffers chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) or multifocal motor neuropathy (MMN).
  • Any subject who has a history of moderate to severe depression, obvious neurological or mental disorder not related to neuropathic pain but may interfere with rating of pain, as well as poly neuropathy, numbness, feeling of pins and needles and weakness in extremities, other serious pain cannot be clearly differentiated from or conditions that may interfere with rating of neuropathic pain. Subjects with weakness but w/o sensory complaints may be included.
  • Any other medical, psychological, or social condition which, in the opinion of the Investigator, would prevent the subject from fully participating in the study, would represent a concern for study compliance, or would constitute a safety concern to the subject.
  • Any subject who has suffered one or more severe hypoglycemia event (defined as neurofunctional hypoglycemia that needs third-party assistance) within 6 months prior to screening.
  • Pain scores \< 3 on the NRS over twice during the one-week run-in period.
  • Any subject with unstable or poorly controlled abnormality in blood pressure or lipid (blood pressure ≥ 160 mmHg/95 mmHg, total cholesterol ≥ 6.2 mmol/L, and/or triglyceride ≥ 6.3 mmol/L) at screening.
  • Any subject with abnormal renal function, estimated (eGFR)\<60 mL/min/1.73 m2.

eGFR=186×Scr\^-1.154×Age\^-0.203×(0.742 for Female)

  • Any subject with abnormal liver function, liver enzymes ( [ALT] and aspartate aminotransferase [AST]) greater than 2 times .
  • Consumed 8 units or more of alcoholic beverages per week for women or 15 units or more of alcoholic beverages per week for men at any time in the 6 months before dosing (1 unit of ethanol is equivalent to 12 ounces of beer, 5 ounces of wine, or 1.5 ounces of spirits) or history of drug or alcohol abuse within the 6 months before dosing or evidence of such abuse as indicated by inquiry, medical history or the laboratory assays conducted during screening. Any subject who has past history of heavy drinking or alcoholism.
  • Any subject who consumes more than 5 cigarettes per day within 30 days before study drug dosing or who cannot stop using any tobacco- or nicotine-containing product during the duration of the trial.
  • Positive screening or check-in alcohol/drugs of abuse/cotinine screen.
  • Positive test results for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at Screening. SARS-CoV-2 testing will be either antigen, nasopharyngeal (NP) or nasal swab polymerase chain reaction (PCR) performed at Day -1, and in accordance with Centers for Disease Control and Prevention (CDC), FDA and local health authorities at the time of enrollment for this study. Participants not willing to comply with the investigational site's Coronavirus Disease 2019 (COVID 19) policy.
  • Female volunteers who are pregnant or lactating.
  • Have a significant acute illness within 7 days prior to study drug administration or have had a major illness or hospitalization within 1 month prior to study drug administration.
  • Systemic or topical use of aspirin or salicylic acid containing products or sulfasalazine/salicylic acid derivatives within 14 days of study drug dosing.
  • Use of other prescription and non-prescription medications (with the exception of permitted concomitant medications, oral , combined estrogen and progestogen containing hormonal contraception and progestogen-only hormonal contraception), such as blood thinners, or sucralfate or herbal preparations within 14 days or 5 half-lives (whichever is longer) before study drug dosing, or use of an over-the-counter medication, vitamins, or supplements (including fish liver oils) within 14 days before study drug dosing.
  • Positive screen on , , or (HIV) at the time of screening evaluations.
  • History of blood donation of more than 500 mL in the last 2 months prior to screening.
  • History or evidence of poor venous access.
  • History of bleeding disorders.
  • Any subject with foot ulcers and/or pedal oedema. Presence of skin disorders, tattoos, skin breakdown, or other skin conditions on either foot that may interfere with the objectives of the study (as per investigator evaluation).
  • Use of any kind of topical lotions, sunscreen, heating pads/cooling pads on feet for at least 24 hours before study drug is administered and until End-of-Study.
  • An employee of the study center or Sponsor or family member of a study center employee
  • Unwilling to stay in the clinical unit for the required duration as per the protocol or consume the standard meal to be provided as per the protocol.
  • Any subject considering or scheduled to undergo any surgical procedure from screening to at least 7 days post dose.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Cohort M1 (10active, 2 placebo)

    296 mg/administration

    Drug: YJ001 for Spray Use · Drug: Placebo of YJ001 for Spray Use

  • Experimental
    Cohort M2 (10 active, 2 placebo)

    414 mg/administration

    Drug: YJ001 for Spray Use · Drug: Placebo of YJ001 for Spray Use

Interventions

  • Granules for spray use; Preparation of Dosing Solution: Reconstitute with sterile water (50ml)

  • DrugPlacebo of YJ001 for Spray Use

    Inactive Ingredient: Sterile water; Preparation of Dosing Solution: 50ml Sterile water

06

What researchers measure

Primary outcomes

  1. Safety Assessments - AEs

    Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)

    Time frame: through study completion, an average of 1year

  2. Safety Assessments -Number of Participants With Abnormal Laboratory Values

    Observed values and changes in baseline of clinical safety laboratory parameters

    Time frame: through study completion, an average of 1year

  3. Safety Assessments - Skin Reaction

    Administration site assessment

    Time frame: through study completion, an average of 1year

Secondary outcomes

  1. Pharmacokinetics-AUC

    Pharmacokinetics of YJ001 and metabolites YJ001-A, YJ001-B, and YJ001-C will be evaluated. Area under the concentration-time curve (AUC)

    Time frame: Day 1-Day 28

  2. Pharmacokinetics- Cmax

    Maximum observed plasma concentration post dose (Cmax)

    Time frame: Day 1-Day 28

  3. Pharmacokinetics - tmax

    Time of maximum observed plasma concentration (tmax)

    Time frame: Day 1-Day 28

  4. Pharmacokinetics - tlag

    Time to first quantifiable plasma concentration (tlag)

    Time frame: Day 1

  5. Pharmacokinetics - t1/2

    t1/2: Apparent terminal elimination half-life post dose

    Time frame: Day 1-Day 28

  6. Pharmacokinetics - CLr/f,ss

    CLr/f,ss: Apparent systemic clearance at steady-state

    Time frame: Day 1 - Day 28

  7. Efficacy evaluation indicator

    Numerical Rating Scale (NRS): at screening, Day -7 to Day 12, NRS score from 0 to 10(integer), the higher score means the more pain

    Time frame: Day -7 - Day 12

  8. Efficacy evaluation indicators

    Average Daily Sleep Interference score (ADSIS): Day 1 to Day 13, ADSIS score from 0 to 10(integer), the higher score means the sleep is more severely affected by pain

    Time frame: Day 1 - Day 13

  9. Efficacy evaluation indicators

    Short-form McGill Pain Questionnaire (SF-MPQ) total scores: Day -1, Day 12.

    Time frame: Day -1, Day 12

  10. Efficacy evaluation indicators

    Vibration perception thresholds (VPT) test (monofilament sensory test)

    Time frame: Day -1, Day 7, Day 11

07

Study locations

1 of 1 sites recruiting
  • Clinical Trials of Texas,LLC
    Fredericksburg, Texas 78229, United States
    Recruiting
    • Douglas Scott Denham · Contact210-949-0122
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2025, 19 months after the start.

Of 171 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's planned 19 months is above that.

Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2024
First posted
Apr 11, 2024
StartActual
May 16, 2024
Primary completionEst.
Dec 20, 2025
CompletionEst.
Jun 30, 2026
Last update
Aug 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06361108
Lead sponsor
Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Apr 11, 2024
Start date
May 16, 2024
Primary completion
Dec 20, 2025 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Aug 13, 2025

Study contacts

Jing Zhang
Contact
zhangjing@zjhanmai.com
86+18602195085
Hainan Yue
Contact
yuehainan@yuejiabiotech.com
86+13166206612
Douglas Scott Denham
principal investigator · 5430 Fredericksburg Rd, Suite 200, San Antonio Texas 78229

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: YJ001

Start the discussion